News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...

Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...

Oikos and its other popular brands are seeing a spike in demand as people taking the weight-loss medications turn to the portion-controlled snacks to meet their nutritional needs.

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)-medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents-have been ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...

A new study uncovers how widely used weight loss drugs like Ozempic impact various health conditions while posing notable ...